<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">KJIM</journal-id>
<journal-title-group>
<journal-title>The Korean Journal of Internal Medicine</journal-title><abbrev-journal-title>Korean J Intern Med</abbrev-journal-title></journal-title-group>
<issn pub-type="ppub">1226-3303</issn>
<issn pub-type="epub">2005-6648</issn>
<publisher>
<publisher-name>The Korean Association of Internal Medicine</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3904/kjim.2016.31.1.98</article-id>
<article-id pub-id-type="publisher-id">kjim-31-1-98</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject><subj-group subj-group-type="heading"><subject>Endocrinology-metabolism</subject></subj-group></subj-group></article-categories>
<title-group>
<article-title>Relationship between metabolic syndrome and thyroid nodules in healthy Koreans</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Shin</surname><given-names>Juyoung</given-names></name>
<xref ref-type="aff" rid="af1-kjim-31-1-98"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Kim</surname><given-names>Min-Hee</given-names></name>
<xref ref-type="aff" rid="af1-kjim-31-1-98"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Yoon</surname><given-names>Kun-Ho</given-names></name>
<xref ref-type="aff" rid="af1-kjim-31-1-98"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Kang</surname><given-names>Moo-Il</given-names></name>
<xref ref-type="aff" rid="af1-kjim-31-1-98"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Cha</surname><given-names>Bong-Yun</given-names></name>
<xref ref-type="aff" rid="af1-kjim-31-1-98"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Lim</surname><given-names>Dong-Jun</given-names></name>
<xref ref-type="aff" rid="af1-kjim-31-1-98"/>
<xref ref-type="corresp" rid="c1-kjim-31-1-98"/>
</contrib>
<aff id="af1-kjim-31-1-98">
Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, <country>Korea</country></aff>
</contrib-group>
<author-notes>
<corresp id="c1-kjim-31-1-98">Correspondence to Dong-Jun Lim, M.D. Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Korea Tel: +82-2-2258-6009 Fax: +82-2-599-3589 E-mail: <email>ldj6026@catholic.ac.kr</email></corresp>
<fn id="fn1-kjim-31-1-98"><p>A portion of these results were presented in abstract form at the 2013 Seoul International Congress of Endocrinology and Metabolism in Seoul, Korea.</p></fn>
</author-notes>
<pub-date pub-type="ppub">
<month>1</month>
<year>2016</year></pub-date>
<pub-date pub-type="epub">
<day>28</day>
<month>12</month>
<year>2015</year></pub-date>
<volume>31</volume>
<issue>1</issue>
<fpage>98</fpage>
<lpage>105</lpage>
<history>
<date date-type="received">
<day>28</day>
<month>04</month>
<year>2014</year></date>
<date date-type="rev-recd">
<day>23</day>
<month>01</month>
<year>2015</year></date>
<date date-type="accepted">
<day>13</day>
<month>05</month>
<year>2015</year></date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2016 The Korean Association of Internal Medicine</copyright-statement>
<copyright-year>2016</copyright-year>
<license>
<license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions>
<abstract>
<sec><title>Background/Aims:</title>
<p>This study evaluated the relationship between thyroid nodules and metabolic syndrome (MS) and its components in apparently healthy Koreans.</p></sec>
<sec><title>Methods:</title>
<p>We reviewed the records of 3,298 subjects with no noticeable symptoms who underwent thyroid ultrasound imaging as part of a routine check-up between July 2009 and June 2010; of these, 1,308 were excluded based upon predefined criteria. Among the remaining 1,990 patients, we examined the association between MS and its components and the incidence of thyroid nodules.</p></sec>
<sec><title>Results:</title>
<p>Of the 1,990 subjects included in this study, 38.4% (n &#x0003d; 764) had thyroid nodules and 12.7% (n &#x0003d; 253) had MS. Female sex, older age, higher body mass index, larger waist circumference, higher glycated hemoglobin level, lower thyroid stimulating hormone level, and presence of MS were all closely related with the presence of thyroid nodules (all <italic>p</italic> &lt; 0.05). Furthermore, the relevant number of MS components showed a positive linear correlation with the occurrence of thyroid nodules (<italic>p</italic> &lt; 0.001). Evidence of MS alone was not independently associated with thyroid nodules after adjusting for sex and age in a multivariate binary logistic regression analysis; however, glycated hemoglobin for females and waist circumference for males, as well as both age and thyroid stimulating hormone for all patients, were identified as independent predictors for the existence of thyroid nodules (all <italic>p</italic> &lt; 0.05).</p></sec>
<sec><title>Conclusions:</title>
<p>This study suggests a positive relationship between the components of MS and thyroid nodules in an ostensibly healthy Korean population. Our data support the idea that the recent increase in thyroid nodules is partly due to increases in both MS and obesity.</p></sec>
</abstract>
<kwd-group>
<kwd>Thyroid nodule</kwd>
<kwd>Metabolic syndrome</kwd>
<kwd>Obesity</kwd>
</kwd-group>
</article-meta></front>
<body>
<sec sec-type="intro">
<title>INTRODUCTION</title>
<p>The incidence of thyroid nodules and subsequent thyroid cancer has increased steadily over the last 30 years. Some of this increase may be due to advances in diagnostic tools, including high-resolution ultrasonography and computed tomography, allowing for greater detection of thyroid nodules, which may not have been detected before &#x0005b;<xref ref-type="bibr" rid="b1-kjim-31-1-98">1</xref>&#x0005d;; however, important changes in the intrinsic characteristics of the general population are also assumed to be involved &#x0005b;<xref ref-type="bibr" rid="b2-kjim-31-1-98">2</xref>&#x0005d;.</p>
<p>Metabolic syndrome (MS) is characterized by a cluster of metabolic risk factors, including central obesity, hypertension, hyperglycemia, and dyslipidemia &#x0005b;<xref ref-type="bibr" rid="b3-kjim-31-1-98">3</xref>&#x0005d;. As modern industrialization has brought a nutritional surplus and sedentary lifestyles to the general population, the prevalence of MS has been rising exponentially worldwide. Recent data have demonstrated that MS is a risk factor not only for cardiovascular disease and diabetes &#x0005b;<xref ref-type="bibr" rid="b4-kjim-31-1-98">4</xref>&#x0005d;but also for tumors, including breast, colorectal, pancreatic, and prostate cancers &#x0005b;<xref ref-type="bibr" rid="b5-kjim-31-1-98">5</xref>-<xref ref-type="bibr" rid="b8-kjim-31-1-98">8</xref>&#x0005d;.</p>
<p>Several previous studies have demonstrated positive associations between MS and thyroid nodules, both benign and malignant, in the general population in Western countries &#x0005b;<xref ref-type="bibr" rid="b9-kjim-31-1-98">9</xref>,<xref ref-type="bibr" rid="b10-kjim-31-1-98">10</xref>&#x0005d;. However, it is not known whether a similar association exists among Asian populations. Here, we designed a cross-sectional study to evaluate the relationship between thyroid nodules and MS and its components in ostensibly healthy Koreans.</p>
</sec>
<sec sec-type="methods">
<title>METHODS</title>
<sec>
<title>Study subjects</title>
<p>We retrospectively reviewed the records of all participants older than 18 years who underwent thyroid ultrasound exams as part of a routine medical check-up at the Health Promotion Center of Seoul St. Mary&#x00027;s Hospital, a major tertiary hospital in Seoul, Korea, from July 2009 to June 2010. Among the 3,298 asymptomatic subjects identified in our initial screen, we excluded subjects who had missing data in questionnaires; had a different racial or ethnic background; had a self-reported history of diabetes, cardiovascular, or thyroid disease; took lipid-lowering agents such as statins or omega-3 fatty acids; or showed abnormalities on thyroid function tests. Ethical approval for the study protocol and data analysis was obtained from the Institutional Review Board of Seoul St. Mary&#x02019;s Hospital.</p>
</sec>
<sec>
<title>Measurement of anthropometric and biochemical parameters</title>
<p>Height and weight were measured without shoes and while wearing light indoor clothes by trained healthcare personnel. Body mass index was calculated as weight divided by height squared (kg/m<sup>2</sup>). Systolic and diastolic blood pressure readings were taken in a sitting position with an automatic device after a 10-minute rest. Waist circumference (WC) was measured at the level above the iliac crest, as defined by National Cholesterol Education Program&#x02019;s Adult Treatment Panel III (NCEP-ATPIII) guidelines &#x0005b;<xref ref-type="bibr" rid="b11-kjim-31-1-98">11</xref>&#x0005d;.</p>
<p>Blood was drawn after an overnight fast. Fasting plasma glucose (FPG) levels were measured in serum with a modified glucose oxidase/peroxidase method (Sekisui Medical, Tokyo, Japan). Glycated hemoglobin (HbA1c) levels were measured with a G7 glycohemoglobin analyzer (Tosoh Bioscience, Tokyo, Japan). Total cholesterol (TC), triglycerides (TGs), high density lipoprotein cholesterol (HDL-C), and low density lipoprotein cholesterol (LDL-C) were determined using standard enzymatic methods (Sekisui Medical). Thyroid stimulating hormone (TSH) and free thyroxine were measured with an electrochemiluminescence immunoassay (Elecsys 1010, Roche, Indianapolis, IN, USA).</p>
<p>MS was defined as the condition in which three or more of the following metabolic components were satisfied, according to NCEP-ATPIII guidelines: (1) WC &#x02265; 90 cm in males, &#x02265; 80 cm in females; (2) TG &#x02265; 150 mg/dL; (3) HDL-C &lt; 40 mg/dL in males, &lt; 50 mg/dL in females; (4) blood pressure &#x02265; 130/85 mmHg or taking antihypertensive medication; and (5) FPG &#x02265; 100 mg/dL.</p>
</sec>
<sec>
<title>Thyroid evaluation</title>
<p>Thyroid ultrasonography was performed by radiologists using an HDI 5000 (Phillips Ultrasound, Bothell, WA, USA) with a 7-15 MHz transducer, according to the standard protocol of the health promotion center. The diagnosis of thyroid nodules was obtained from a review of radiological reports. A thyroid nodule was defined as discrete lesions distinct from the surrounding thyroid parenchyma, and which had a solid portion regardless of the presence of a cystic portion. The maximal diameter of a thyroid nodule was measured in three planes: longitudinal, transverse, and anteroposterior.</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>Categorical data are expressed as numbers and percentages of subjects. Continuous variables are expressed as the mean &#x000b1; standard deviation. To evaluate differences in metabolic parameters between those with and without thyroid nodules, categorical variables were analyzed based on the chi-square test and continuous variables were compared with the unpaired <italic>t</italic> test. To find any association between metabolic components and the prevalence of thyroid nodules, we analyzed the data using a binary logistic regression analysis. A multivariate binary logistic regression analysis was used to determine independent factors for predicting the occurrence of thyroid nodules. A <italic>p</italic> &lt; 0.05 was considered statistically significant. All analyses were performed using SPSS version 15.0 (SPSS Inc., Chicago, IL, USA).</p>
</sec>
</sec>
<sec sec-type="results">
<title>RESULTS</title>
<sec>
<title>Clinical characteristics of the study subjects</title>
<p>A total of 3,298 subjects were identified who underwent thyroid ultrasound exams as part of a general health check-up. Subjects were excluded from analysis based upon: (1) missing data in patient questionnaires (n &#x0003d; 156); (2) unknown race or ethnicity (n &#x0003d; 63); (3) known thyroid disease (n &#x0003d; 180); (4) use of lipid-lowering agents, including statins or omega-3 fatty acids (n &#x0003d; 279); (5) history of diabetes (n &#x0003d; 175) or cardiovascular disease (n &#x0003d; 123); or (6) thyroid dysfunction (n &#x0003d; 332) (<xref rid="f1-kjim-31-1-98" ref-type="fig">Fig. 1</xref>). Based upon these criteria, we were able to identify 1,990 subjects for inclusion in the final study population.</p>
</sec>
<sec>
<title>Metabolic variables and thyroid nodules</title>
<p>The baseline characteristics of the study subjects are summarized in <xref rid="t1-kjim-31-1-98" ref-type="table">Tables 1</xref> and <xref rid="t2-kjim-31-1-98" ref-type="table">2</xref>. Among the 1,990 subjects in the final analysis, 764 (38.4%) had thyroid nodules and 253 (12.7%) had MS. The study population consisted of 1,299 females (65.3%) and had a mean age of 49.8 &#x000b1; 10.0 years.</p>
<p>Subjects with thyroid nodules showed a higher female to male ratio (70.8% vs. 61.8%, <italic>p</italic> &lt; 0.001) and older age (52.4 &#x000b1; 9.5 years vs. 48.2 &#x000b1; 10.0 years, <italic>p</italic> &lt; 0.001) relative to those without thyroid nodules. The prevalence of MS was also higher in subjects with thyroid nodules than in those without (115/764 &#x0005b;15.1%&#x0005d; vs. 138/1,226 &#x0005b;11.3%&#x0005d;, <italic>p</italic> &#x0003d; 0.015). Body mass index, WC, and HbA1c were significantly higher in subjects with thyroid nodules, while blood pressure, FPG, and lipid profiles, including TC, TG, HDL-C, and LDL-C, showed no statistically significant difference between groups. Subjects with MS had a higher prevalence of not only thyroid nodules but also nodules larger than 1 cm (<xref rid="t2-kjim-31-1-98" ref-type="table">Table 2</xref>). However, the prevalence of multiple thyroid nodules did not differ between subjects with or without MS.</p>
<p>Subjects with MS showed a lower female to male ratio (56.9% vs. 66.5%, <italic>p</italic> &#x0003d; 0.004) and a higher prevalence of thyroid nodules (45.5% vs. 37.4%, <italic>p</italic> &#x0003d; 0.015) than those without MS. The mean age of the subjects with MS was higher, though this difference was not statistically significant (54.9 &#x000b1; 9.0 years vs. 49.1 &#x000b1; 9.9 years, <italic>p</italic> &#x0003d; 0.058).</p>
<p>As the number of MS components satisfied increased, the proportion of patients with thyroid nodules rose, indicating a strong correlation between MS and thyroid nodules (&#x003b2; &#x0003d; 1.235, <italic>p</italic> &lt; 0.001) (<xref rid="f2-kjim-31-1-98" ref-type="fig">Fig. 2</xref>). However, individual components of MS did not show independent relationships with thyroid nodules after adjusting for sex and age. Moreover, age stratification showed that the prevalence of both thyroid nodules and MS was closely associated with age (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 1</xref>). To address these apparent discrepancies, we ran a multivariate binary logistic regression analysis to identify clinical variables that could independently predict the existence of thyroid nodules (<xref rid="t3-kjim-31-1-98" ref-type="table">Table 3</xref>). HbA1c levels were a significant predictor of thyroid nodules in females (<italic>p</italic> &#x0003d; 0.011), while WC was a significant predictor only in males (<italic>p</italic> &#x0003d; 0.005); higher age and lower TSH were significant factors for predicting thyroid nodules in both sexes (<italic>p</italic> &lt; 0.001).</p>
</sec>
</sec>
<sec sec-type="discussion">
<title>DISCUSSION</title>
<p>In this study, we explored the relationship between the presence of thyroid nodules and the components of MS in ostensibly healthy Koreans with no evidence of iodine insufficiency &#x0005b;<xref ref-type="bibr" rid="b12-kjim-31-1-98">12</xref>&#x0005d;. Our results suggest an association between thyroid nodules and MS components even in healthy populations, which may have important implications for the diagnosis and treatment of thyroid-related diseases.</p>
<p>MS is closely associated with an increase in overall mortality, due not only to increases in cardiovascular complications &#x0005b;<xref ref-type="bibr" rid="b4-kjim-31-1-98">4</xref>&#x0005d;, but also malignant diseases &#x0005b;<xref ref-type="bibr" rid="b5-kjim-31-1-98">5</xref>-<xref ref-type="bibr" rid="b8-kjim-31-1-98">8</xref>&#x0005d;. Insulin resistance, a characteristic manifestation of MS, increases glucose and insulin levels, which stimulate cell proliferation. Large population studies revealed that patients with glucose metabolism disorders have a higher chance of both malignancy and mortality &#x0005b;<xref ref-type="bibr" rid="b5-kjim-31-1-98">5</xref>,<xref ref-type="bibr" rid="b13-kjim-31-1-98">13</xref>-<xref ref-type="bibr" rid="b16-kjim-31-1-98">16</xref>&#x0005d;. The tumorigenic effects of MS appear to be mediated through changes in cytokine levels, resulting in decreased expression of tumor suppression genes, and increases in oncogene expression due to inflammation and reactive oxygen species generation; other factors, such as the stimulation of angiogenesis and invasion of malignant cells into normal tissues, may also play a role &#x0005b;<xref ref-type="bibr" rid="b5-kjim-31-1-98">5</xref>&#x0005d;. While many of the mechanisms underlying these effects remain poorly understood, these activities are well supported by a variety of observational and laboratory studies.</p>
<p>Recent studies suggest that components of MS are possible risk factors for thyroid nodules, beyond many of the well-established ones, including sex, goiter, family history of thyroid cancer, and radiation exposure. MS is thought to trigger thyroid nodules via the stimulation of thyroid proliferation and angiogenesis brought on by hyperinsulinemia, hyperglycemia, and dyslipidemia &#x0005b;<xref ref-type="bibr" rid="b17-kjim-31-1-98">17</xref>-<xref ref-type="bibr" rid="b19-kjim-31-1-98">19</xref>&#x0005d;. Our data demonstrate that people with MS had a higher prevalence of thyroid nodules. The subjects with MS also had a higher prevalence of thyroid nodules larger than 1 cm, consistent with a previous study showing a positive association between insulin resistance and thyroid nodule size &#x0005b;<xref ref-type="bibr" rid="b19-kjim-31-1-98">19</xref>&#x0005d;. Furthermore, we showed that the number of accompanying MS factors had a significant positive correlation with the prevalence of thyroid nodules; the more components of MS were observed, the higher the chance of thyroid nodules. The prevalence of thyroid nodules may be affected by sex &#x0005b;<xref ref-type="bibr" rid="b20-kjim-31-1-98">20</xref>,<xref ref-type="bibr" rid="b21-kjim-31-1-98">21</xref>&#x0005d;; as older age was also positively correlated with not only the presence of thyroid nodules, but also MS &#x0005b;<xref ref-type="bibr" rid="b22-kjim-31-1-98">22</xref>&#x0005d;, we analyzed the role of sex independently using multivariate logistic regression. After adjusting for age, higher HbA1c in females and larger WC in males were found to be significant factors for the presence of thyroid nodules.</p>
<p>Many previous studies have shown that hyperglycemia has a strong correlation with thyroid cancer in both sexes &#x0005b;<xref ref-type="bibr" rid="b23-kjim-31-1-98">23</xref>,<xref ref-type="bibr" rid="b24-kjim-31-1-98">24</xref>&#x0005d;. Our study demonstrates that hyperglycemia, as indicated by HbA1c levels, showed a significant relationship with the presence of thyroid nodules in women. An interesting finding is that HbA1c levels showed a significant association with thyroid nodules both before and after adjustment for related factors, whereas FPG levels did not. The exclusion of all known diabetic patients to target a metabolically normal population might make these two hyperglycemia-related parameters contradictory. Consistent with our study, a previous univariate analysis of an Icelandic cohort showed the relative risk for women with high 90-minute postprandial glucose levels for thyroid cancer was 1.12 &#x0005b;<xref ref-type="bibr" rid="b14-kjim-31-1-98">14</xref>&#x0005d;, indicating that postprandial glucose levels may be associated with thyroid nodules and, potentially, thyroid cancer. Although the effects of postprandial hyperglycemia on tumor formation have been not well evaluated, hyperglycemia, oxidative stress, endothelial dysfunction, and the formation of advanced glycation end products may all potentially be involved in the pathophysiology of tumor formation &#x0005b;<xref ref-type="bibr" rid="b5-kjim-31-1-98">5</xref>,<xref ref-type="bibr" rid="b25-kjim-31-1-98">25</xref>,<xref ref-type="bibr" rid="b26-kjim-31-1-98">26</xref>&#x0005d;. As HbA1c levels are routinely used to screen for the existence of diabetes &#x0005b;<xref ref-type="bibr" rid="b27-kjim-31-1-98">27</xref>-<xref ref-type="bibr" rid="b30-kjim-31-1-98">30</xref>&#x0005d;, our center was able to measure these levels across all patients; however, we were unable to evaluate insulin resistance outcomes, such as homeostasis model assessment of insulin resistance, as neither insulin nor c-peptide were routinely measured.</p>
<p>Anthropometric measurements showed inconsistent associations with the prevalence of thyroid cancer. Most studies that have evaluated the relationship between body mass index and thyroid cancer have reported a strong association between them &#x0005b;<xref ref-type="bibr" rid="b14-kjim-31-1-98">14</xref>,<xref ref-type="bibr" rid="b31-kjim-31-1-98">31</xref>,<xref ref-type="bibr" rid="b32-kjim-31-1-98">32</xref>&#x0005d;; however, the significance varied with sex. Kitahara et al. &#x0005b;<xref ref-type="bibr" rid="b33-kjim-31-1-98">33</xref>&#x0005d; demonstrated a slightly stronger association of WC and weight change with thyroid cancer risk in men versus women, which may be due to a difference in hormone profiles, such as leptin and estrogen, and the metabolic consequences of excess body fat in men and women.</p>
<p>TSH levels were inversely related with thyroid nodules, even though both TSH levels were within normal ranges. One possible explanation is that multiple thyroid nodules could maintain TSH levels at a lower normal range by autonomous hyperfunctioning. TSH has been shown to be suppressed in patients with a multinodular goiter &#x0005b;<xref ref-type="bibr" rid="b34-kjim-31-1-98">34</xref>&#x0005d;, while TSH levels &lt; 2.5 mIU/L may be related to an increased risk of MS &#x0005b;<xref ref-type="bibr" rid="b35-kjim-31-1-98">35</xref>&#x0005d;. These associations were not replicated in our study, with MS patients showing no increases in TSH levels (<xref rid="t2-kjim-31-1-98" ref-type="table">Table 2</xref>). This difference may be an artifact of the study design, as our study population consisted entirely of patients who underwent thyroid ultrasound imaging.</p>
<p>Our study has several unique clinical features. The most important aspect of this study is its use of clinically healthy subjects. Because we initially excluded all subjects with a history of diabetes or cardiovascular disease and those taking lipid-lowering agents, the prevalence of MS (12.7%) in our study population was much lower than that in the general Korean population, with MS prevalence rates estimated at 31.3% &#x0005b;<xref ref-type="bibr" rid="b36-kjim-31-1-98">36</xref>&#x0005d;. Although the strict inclusion criteria may have underestimated the effects of abnormal glucose and lipid metabolism on the thyroid, MS components showed significant connections with thyroid nodules. Second, this analysis was based on reliable parameters measured by specialists using standardized methods at a single center. The large number of subjects enrolled is also an important strength of this study.</p>
<p>Despite its many strengths, this study is not without limitations. First, it was a retrospective, cross-sectional study. Therefore, the study population might be biased, as the study population consisted of people who determined by themselves whether they should undergo thyroid ultrasonography. This aspect of the study design may explain why the prevalence of thyroid nodules was similar between sexes, unlike a previous study &#x0005b;<xref ref-type="bibr" rid="b21-kjim-31-1-98">21</xref>&#x0005d;. A longitudinal cohort study with a more representative population will be needed to address these potential issues. Second, we could not evaluate the association between insulin resistance and thyroid nodules because insulin and C-peptide levels were not available. A lack of cytological or histological results for each nodule is an important limitation. Future studies focusing on more biopsy-proven reports and with a longer follow-up duration will be necessary to provide a more complete and accurate evaluation of the relationship.</p>
<p>This study suggests an association between the components of MS and thyroid nodules in a healthy Korean population. Our data show that female sex, older age, lower TSH, and higher number of accompanying MS components were all positively associated with the presence of thyroid nodules. Future studies evaluating the effects of active interventions, including lifestyle modification and medication adjustments, on components of MS with regard to the incidence of thyroid nodules and, ultimately, the prevention of thyroid cancer, are therefore warranted.</p>
</sec>
<sec>
<title>KEY MESSAGE</title>
<boxed-text position="float" orientation="portrait">
<p>1. There is a positive relationship between the components of metabolic syndrome (MS) and thyroid nodules in an ostensibly healthy Korean population.</p>
<p>2. A recent increase in thyroid nodules is partly due to increases in both MS and obesity.</p>
</boxed-text>
</sec>
</body>
<back>
<fn-group><fn fn-type="conflict"><p>No potential conflict of interest relevant to this article was reported.</p></fn></fn-group>
<sec sec-type="supplementary-material"><title>Supplementary Material</title>
<supplementary-material content-type="loca-data" id="SD1">
<label>Supplementary Figure 1.</label><caption>
<p>Association between age and the prevalence of metabolic syndrome (MS) and thyroid nodules.</p>
</caption><media mimetype="image" mime-subtype="pdf" xlink:href="kjim-31-1-98-supple1.pdf"/></supplementary-material>
</sec>
<ref-list>
<title>REFERENCES</title>
<ref id="b1-kjim-31-1-98">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Davies</surname><given-names>L</given-names></name>
<name><surname>Welch</surname><given-names>HG</given-names></name>
</person-group>
<article-title>Increasing incidence of thyroid cancer in the United States, 1973-2002</article-title>
<source>JAMA</source>
<year>2006</year>
<volume>295</volume>
<fpage>2164</fpage>
<lpage>2167</lpage>
</element-citation></ref>
<ref id="b2-kjim-31-1-98">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Enewold</surname><given-names>L</given-names></name>
<name><surname>Zhu</surname><given-names>K</given-names></name>
<name><surname>Ron</surname><given-names>E</given-names></name>
<etal/>
</person-group>
<article-title>Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005</article-title>
<source>Cancer Epidemiol Biomarkers Prev</source>
<year>2009</year>
<volume>18</volume>
<fpage>784</fpage>
<lpage>791</lpage>
</element-citation></ref>
<ref id="b3-kjim-31-1-98">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Eckel</surname><given-names>RH</given-names></name>
<name><surname>Grundy</surname><given-names>SM</given-names></name>
<name><surname>Zimmet</surname><given-names>PZ</given-names></name>
</person-group>
<article-title>The metabolic syndrome</article-title>
<source>Lancet</source>
<year>2005</year>
<volume>365</volume>
<fpage>1415</fpage>
<lpage>1428</lpage>
</element-citation></ref>
<ref id="b4-kjim-31-1-98">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lorenzo</surname><given-names>C</given-names></name>
<name><surname>Williams</surname><given-names>K</given-names></name>
<name><surname>Hunt</surname><given-names>KJ</given-names></name>
<name><surname>Haffner</surname><given-names>SM</given-names></name>
</person-group>
<article-title>The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes</article-title>
<source>Diabetes Care</source>
<year>2007</year>
<volume>30</volume>
<fpage>8</fpage>
<lpage>13</lpage>
</element-citation></ref>
<ref id="b5-kjim-31-1-98">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pothiwala</surname><given-names>P</given-names></name>
<name><surname>Jain</surname><given-names>SK</given-names></name>
<name><surname>Yaturu</surname><given-names>S</given-names></name>
</person-group>
<article-title>Metabolic syndrome and cancer</article-title>
<source>Metab Syndr Relat Disord</source>
<year>2009</year>
<volume>7</volume>
<fpage>279</fpage>
<lpage>288</lpage>
</element-citation></ref>
<ref id="b6-kjim-31-1-98">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Esposito</surname><given-names>K</given-names></name>
<name><surname>Chiodini</surname><given-names>P</given-names></name>
<name><surname>Capuano</surname><given-names>A</given-names></name>
<etal/>
</person-group>
<article-title>Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis</article-title>
<source>Menopause</source>
<year>2013</year>
<volume>20</volume>
<fpage>1301</fpage>
<lpage>1309</lpage>
</element-citation></ref>
<ref id="b7-kjim-31-1-98">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Russo</surname><given-names>A</given-names></name>
<name><surname>Autelitano</surname><given-names>M</given-names></name>
<name><surname>Bisanti</surname><given-names>L</given-names></name>
</person-group>
<article-title>Metabolic syndrome and cancer risk</article-title>
<source>Eur J Cancer</source>
<year>2008</year>
<volume>44</volume>
<fpage>293</fpage>
<lpage>297</lpage>
</element-citation></ref>
<ref id="b8-kjim-31-1-98">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lund Haheim</surname><given-names>L</given-names></name>
<name><surname>Wisloff</surname><given-names>TF</given-names></name>
<name><surname>Holme</surname><given-names>I</given-names></name>
<name><surname>Nafstad</surname><given-names>P</given-names></name>
</person-group>
<article-title>Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years</article-title>
<source>Am J Epidemiol</source>
<year>2006</year>
<volume>164</volume>
<fpage>769</fpage>
<lpage>774</lpage>
</element-citation></ref>
<ref id="b9-kjim-31-1-98">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ayturk</surname><given-names>S</given-names></name>
<name><surname>Gursoy</surname><given-names>A</given-names></name>
<name><surname>Kut</surname><given-names>A</given-names></name>
<name><surname>Anil</surname><given-names>C</given-names></name>
<name><surname>Nar</surname><given-names>A</given-names></name>
<name><surname>Tutuncu</surname><given-names>NB</given-names></name>
</person-group>
<article-title>Metabolic syndrome and its components are associated with increased thyroid volume and nodule prevalence in a mild-to-moderate iodine-deficient area</article-title>
<source>Eur J Endocrinol</source>
<year>2009</year>
<volume>161</volume>
<fpage>599</fpage>
<lpage>605</lpage>
</element-citation></ref>
<ref id="b10-kjim-31-1-98">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Rezzonico</surname><given-names>JN</given-names></name>
<name><surname>Rezzonico</surname><given-names>M</given-names></name>
<name><surname>Pusiol</surname><given-names>E</given-names></name>
<name><surname>Pitoia</surname><given-names>F</given-names></name>
<name><surname>Niepomniszcze</surname><given-names>H</given-names></name>
</person-group>
<article-title>Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma</article-title>
<source>Metab Syndr Relat Disord</source>
<year>2009</year>
<volume>7</volume>
<fpage>375</fpage>
<lpage>380</lpage>
</element-citation></ref>
<ref id="b11-kjim-31-1-98">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults</collab>
</person-group>
<article-title>Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)</article-title>
<source>JAMA</source>
<year>2001</year>
<volume>285</volume>
<fpage>2486</fpage>
<lpage>2497</lpage>
</element-citation></ref>
<ref id="b12-kjim-31-1-98">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>JY</given-names></name>
<name><surname>Kim</surname><given-names>KR</given-names></name>
</person-group>
<article-title>Dietary iodine intake and urinary iodine excretion in patients with thyroid diseases</article-title>
<source>Yonsei Med J</source>
<year>2000</year>
<volume>41</volume>
<fpage>22</fpage>
<lpage>28</lpage>
</element-citation></ref>
<ref id="b13-kjim-31-1-98">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Saydah</surname><given-names>SH</given-names></name>
<name><surname>Loria</surname><given-names>CM</given-names></name>
<name><surname>Eberhardt</surname><given-names>MS</given-names></name>
<name><surname>Brancati</surname><given-names>FL</given-names></name>
</person-group>
<article-title>Abnormal glucose tolerance and the risk of cancer death in the United States</article-title>
<source>Am J Epidemiol</source>
<year>2003</year>
<volume>157</volume>
<fpage>1092</fpage>
<lpage>1100</lpage>
</element-citation></ref>
<ref id="b14-kjim-31-1-98">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tulinius</surname><given-names>H</given-names></name>
<name><surname>Sigfusson</surname><given-names>N</given-names></name>
<name><surname>Sigvaldason</surname><given-names>H</given-names></name>
<name><surname>Bjarnadottir</surname><given-names>K</given-names></name>
<name><surname>Tryggvadottir</surname><given-names>L</given-names></name>
</person-group>
<article-title>Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders</article-title>
<source>Cancer Epidemiol Biomarkers Prev</source>
<year>1997</year>
<volume>6</volume>
<fpage>863</fpage>
<lpage>873</lpage>
</element-citation></ref>
<ref id="b15-kjim-31-1-98">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Calle</surname><given-names>EE</given-names></name>
<name><surname>Kaaks</surname><given-names>R</given-names></name>
</person-group>
<article-title>Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms</article-title>
<source>Nat Rev Cancer</source>
<year>2004</year>
<volume>4</volume>
<fpage>579</fpage>
<lpage>591</lpage>
</element-citation></ref>
<ref id="b16-kjim-31-1-98">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ibrahim</surname><given-names>YH</given-names></name>
<name><surname>Yee</surname><given-names>D</given-names></name>
</person-group>
<article-title>Insulin-like growth factor-I and cancer risk</article-title>
<source>Growth Horm IGF Res</source>
<year>2004</year>
<volume>14</volume>
<fpage>261</fpage>
<lpage>269</lpage>
</element-citation></ref>
<ref id="b17-kjim-31-1-98">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Iribarren</surname><given-names>C</given-names></name>
<name><surname>Haselkorn</surname><given-names>T</given-names></name>
<name><surname>Tekawa</surname><given-names>IS</given-names></name>
<name><surname>Friedman</surname><given-names>GD</given-names></name>
</person-group>
<article-title>Cohort study of thyroid cancer in a San Francisco Bay area population</article-title>
<source>Int J Cancer</source>
<year>2001</year>
<volume>93</volume>
<fpage>745</fpage>
<lpage>750</lpage>
</element-citation></ref>
<ref id="b18-kjim-31-1-98">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yin</surname><given-names>J</given-names></name>
<name><surname>Wang</surname><given-names>C</given-names></name>
<name><surname>Shao</surname><given-names>Q</given-names></name>
<etal/>
</person-group>
<article-title>Relationship between the prevalence of thyroid nodules and metabolic syndrome in the iodine-adequate area of Hangzhou, China: a cross-sectional and cohort study</article-title>
<source>Int J Endocrinol</source>
<year>2014</year>
<volume>2014</volume>
<fpage>675796</fpage>
</element-citation></ref>
<ref id="b19-kjim-31-1-98">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>K</given-names></name>
<name><surname>Yang</surname><given-names>Y</given-names></name>
<name><surname>Wu</surname><given-names>Y</given-names></name>
<etal/>
</person-group>
<article-title>The association between insulin resistance and vascularization of thyroid nodules</article-title>
<source>J Clin Endocrinol Metab</source>
<year>2015</year>
<volume>100</volume>
<fpage>184</fpage>
<lpage>192</lpage>
</element-citation></ref>
<ref id="b20-kjim-31-1-98">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mazzaferri</surname><given-names>EL</given-names></name>
</person-group>
<article-title>Management of a solitary thyroid nodule</article-title>
<source>N Engl J Med</source>
<year>1993</year>
<volume>328</volume>
<fpage>553</fpage>
<lpage>559</lpage>
</element-citation></ref>
<ref id="b21-kjim-31-1-98">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>JY</given-names></name>
<name><surname>Jung</surname><given-names>EJ</given-names></name>
<name><surname>Park</surname><given-names>ST</given-names></name>
<etal/>
</person-group>
<article-title>Body size and thyroid nodules in healthy Korean population</article-title>
<source>J Korean Surg Soc</source>
<year>2012</year>
<volume>82</volume>
<fpage>13</fpage>
<lpage>17</lpage>
</element-citation></ref>
<ref id="b22-kjim-31-1-98">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hildrum</surname><given-names>B</given-names></name>
<name><surname>Mykletun</surname><given-names>A</given-names></name>
<name><surname>Hole</surname><given-names>T</given-names></name>
<name><surname>Midthjell</surname><given-names>K</given-names></name>
<name><surname>Dahl</surname><given-names>AA</given-names></name>
</person-group>
<article-title>Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study</article-title>
<source>BMC Public Health</source>
<year>2007</year>
<volume>7</volume>
<fpage>220</fpage>
</element-citation></ref>
<ref id="b23-kjim-31-1-98">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhan</surname><given-names>YS</given-names></name>
<name><surname>Feng</surname><given-names>L</given-names></name>
<name><surname>Tang</surname><given-names>SH</given-names></name>
<etal/>
</person-group>
<article-title>Glucose metabolism disorders in cancer patients in a Chinese population</article-title>
<source>Med Oncol</source>
<year>2010</year>
<volume>27</volume>
<fpage>177</fpage>
<lpage>184</lpage>
</element-citation></ref>
<ref id="b24-kjim-31-1-98">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zivaljevic</surname><given-names>V</given-names></name>
<name><surname>Vlajinac</surname><given-names>H</given-names></name>
<name><surname>Jankovic</surname><given-names>R</given-names></name>
<name><surname>Marinkovic</surname><given-names>J</given-names></name>
<name><surname>Diklic</surname><given-names>A</given-names></name>
<name><surname>Paunovic</surname><given-names>I</given-names></name>
</person-group>
<article-title>Case-control study of anaplastic thyroid cancer</article-title>
<source>Tumori</source>
<year>2004</year>
<volume>90</volume>
<fpage>9</fpage>
<lpage>12</lpage>
</element-citation></ref>
<ref id="b25-kjim-31-1-98">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gerich</surname><given-names>JE</given-names></name>
</person-group>
<article-title>Clinical significance, pathogenesis, and management of postprandial hyperglycemia</article-title>
<source>Arch Intern Med</source>
<year>2003</year>
<volume>163</volume>
<fpage>1306</fpage>
<lpage>1316</lpage>
</element-citation></ref>
<ref id="b26-kjim-31-1-98">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Heine</surname><given-names>RJ</given-names></name>
<name><surname>Balkau</surname><given-names>B</given-names></name>
<name><surname>Ceriello</surname><given-names>A</given-names></name>
<name><surname>Del Prato</surname><given-names>S</given-names></name>
<name><surname>Horton</surname><given-names>ES</given-names></name>
<name><surname>Taskinen</surname><given-names>MR</given-names></name>
</person-group>
<article-title>What does postprandial hyperglycaemia mean?</article-title>
<source>Diabet Med</source>
<year>2004</year>
<volume>21</volume>
<fpage>208</fpage>
<lpage>213</lpage>
</element-citation></ref>
<ref id="b27-kjim-31-1-98">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ko</surname><given-names>SH</given-names></name>
<name><surname>Kim</surname><given-names>SR</given-names></name>
<name><surname>Kim</surname><given-names>DJ</given-names></name>
<etal/>
</person-group>
<article-title>2011 Clinical practice guidelines for type 2 diabetes in Korea</article-title>
<source>Diabetes Metab J</source>
<year>2011</year>
<volume>35</volume>
<fpage>431</fpage>
<lpage>436</lpage>
</element-citation></ref>
<ref id="b28-kjim-31-1-98">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>International Expert Committee</collab>
</person-group>
<article-title>International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes</article-title>
<source>Diabetes Care</source>
<year>2009</year>
<volume>32</volume>
<fpage>1327</fpage>
<lpage>1334</lpage>
</element-citation></ref>
<ref id="b29-kjim-31-1-98">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Saudek</surname><given-names>CD</given-names></name>
<name><surname>Herman</surname><given-names>WH</given-names></name>
<name><surname>Sacks</surname><given-names>DB</given-names></name>
<name><surname>Bergenstal</surname><given-names>RM</given-names></name>
<name><surname>Edelman</surname><given-names>D</given-names></name>
<name><surname>Davidson</surname><given-names>MB</given-names></name>
</person-group>
<article-title>A new look at screening and diagnosing diabetes mellitus</article-title>
<source>J Clin Endocrinol Metab</source>
<year>2008</year>
<volume>93</volume>
<fpage>2447</fpage>
<lpage>2453</lpage>
</element-citation></ref>
<ref id="b30-kjim-31-1-98">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bennett</surname><given-names>CM</given-names></name>
<name><surname>Guo</surname><given-names>M</given-names></name>
<name><surname>Dharmage</surname><given-names>SC</given-names></name>
</person-group>
<article-title>HbA(1c) as a screening tool for detection of type 2 diabetes: a systematic review</article-title>
<source>Diabet Med</source>
<year>2007</year>
<volume>24</volume>
<fpage>333</fpage>
<lpage>343</lpage>
</element-citation></ref>
<ref id="b31-kjim-31-1-98">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Dal Maso</surname><given-names>L</given-names></name>
<name><surname>La Vecchia</surname><given-names>C</given-names></name>
<name><surname>Franceschi</surname><given-names>S</given-names></name>
<etal/>
</person-group>
<article-title>A pooled analysis of thyroid cancer studies. V. Anthropometric factors</article-title>
<source>Cancer Causes Control</source>
<year>2000</year>
<volume>11</volume>
<fpage>137</fpage>
<lpage>144</lpage>
</element-citation></ref>
<ref id="b32-kjim-31-1-98">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Engeland</surname><given-names>A</given-names></name>
<name><surname>Tretli</surname><given-names>S</given-names></name>
<name><surname>Akslen</surname><given-names>LA</given-names></name>
<name><surname>Bjorge</surname><given-names>T</given-names></name>
</person-group>
<article-title>Body size and thyroid cancer in two million Norwegian men and women</article-title>
<source>Br J Cancer</source>
<year>2006</year>
<volume>95</volume>
<fpage>366</fpage>
<lpage>370</lpage>
</element-citation></ref>
<ref id="b33-kjim-31-1-98">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kitahara</surname><given-names>CM</given-names></name>
<name><surname>Platz</surname><given-names>EA</given-names></name>
<name><surname>Park</surname><given-names>Y</given-names></name>
<name><surname>Hollenbeck</surname><given-names>AR</given-names></name>
<name><surname>Schatzkin</surname><given-names>A</given-names></name>
<name><surname>Berrington de Gonzalez</surname><given-names>A</given-names></name>
</person-group>
<article-title>Body fat distribution, weight change during adulthood, and thyroid cancer risk in the NIH-AARP Diet and Health Study</article-title>
<source>Int J Cancer</source>
<year>2012</year>
<volume>130</volume>
<fpage>1411</fpage>
<lpage>1419</lpage>
</element-citation></ref>
<ref id="b34-kjim-31-1-98">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Elte</surname><given-names>JW</given-names></name>
<name><surname>Bussemaker</surname><given-names>JK</given-names></name>
<name><surname>Haak</surname><given-names>A</given-names></name>
</person-group>
<article-title>The natural history of euthyroid multinodular goitre</article-title>
<source>Postgrad Med J</source>
<year>1990</year>
<volume>66</volume>
<fpage>186</fpage>
<lpage>190</lpage>
</element-citation></ref>
<ref id="b35-kjim-31-1-98">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Oh</surname><given-names>JY</given-names></name>
<name><surname>Sung</surname><given-names>YA</given-names></name>
<name><surname>Lee</surname><given-names>HJ</given-names></name>
</person-group>
<article-title>Elevated thyroid stimulating hormone levels are associated with metabolic syndrome in euthyroid young women</article-title>
<source>Korean J Intern Med</source>
<year>2013</year>
<volume>28</volume>
<fpage>180</fpage>
<lpage>186</lpage>
</element-citation></ref>
<ref id="b36-kjim-31-1-98">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lim</surname><given-names>S</given-names></name>
<name><surname>Shin</surname><given-names>H</given-names></name>
<name><surname>Song</surname><given-names>JH</given-names></name>
<etal/>
</person-group>
<article-title>Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007</article-title>
<source>Diabetes Care</source>
<year>2011</year>
<volume>34</volume>
<fpage>1323</fpage>
<lpage>1328</lpage>
</element-citation></ref>
</ref-list>
<sec sec-type="display-objects">
<title>Figures and Tables</title>
<fig id="f1-kjim-31-1-98" position="float">
<label>Figure 1.</label><caption><p>Selection of study participants.</p></caption>
<graphic xlink:href="kjim-31-1-98f1.tif"/>
</fig>
<fig id="f2-kjim-31-1-98" position="float">
<label>Figure 2.</label><caption><p>Association between the number of relevant components of metabolic syndrome (MS) and prevalence of thyroid nodules.</p></caption>
<graphic xlink:href="kjim-31-1-98f2.tif"/>
</fig>
<table-wrap id="t1-kjim-31-1-98" position="float">
<label>Table 1.</label>
<caption><p>Metabolic variables and presence of thyroid nodules in subjects with and without thyroid nodules</p></caption>
<table rules="groups" frame="hsides">
<thead><tr>
<th align="left" valign="middle">Variable</th>
<th align="center" valign="middle">Total (n = 1,990)</th>
<th align="center" valign="middle">With thyroid nodule (n = 764)</th>
<th align="center" valign="middle">Without thyroid nodule (n = 1,226)</th>
<th align="center" valign="middle"><italic>p</italic> value<sup><xref rid="tfn1-kjim-31-1-98" ref-type="table-fn">a</xref></sup></th>
</tr></thead>
<tbody>
<tr>
<td align="left" valign="top">Male sex</td>
<td align="center" valign="top">691 (34.7)</td>
<td align="center" valign="top">223 (29.2)</td>
<td align="center" valign="top">468 (38.2)</td>
<td align="center" valign="top">&lt; 0.001</td>
</tr>
<tr>
<td align="left" valign="top">Age, yr</td>
<td align="center" valign="top">49.8 &#x000B1; 10.0</td>
<td align="center" valign="top">52.4 &#x000B1; 9.5</td>
<td align="center" valign="top">48.2 &#x000B1; 10.0</td>
<td align="center" valign="top">&lt; 0.001</td>
</tr>
<tr>
<td align="left" valign="top">Systolic blood pressure, mmHg</td>
<td align="center" valign="top">118.4 &#x000B1; 14.3</td>
<td align="center" valign="top">119.2&#x000B1; 14.3</td>
<td align="center" valign="top">118.0 &#x000B1; 14.3</td>
<td align="center" valign="top">0.073</td>
</tr>
<tr>
<td align="left" valign="top">Diastolic blood pressure, mmHg</td>
<td align="center" valign="top">69.2 &#x000B1; 10.1</td>
<td align="center" valign="top">69.5&#x000B1; 10.2</td>
<td align="center" valign="top">69.0 &#x000B1; 10.1</td>
<td align="center" valign="top">0.279</td>
</tr>
<tr>
<td align="left" valign="top">Body mass index, kg/m<sup>2</sup></td>
<td align="center" valign="top">22.9 &#x000B1; 3.1</td>
<td align="center" valign="top">23.2 &#x000B1; 3.0</td>
<td align="center" valign="top">22.7 &#x000B1; 3.1</td>
<td align="center" valign="top">0.001</td>
</tr>
<tr>
<td align="left" valign="top">Waist circumference, cm</td>
<td align="center" valign="top">82.3 &#x000B1; 8.1</td>
<td align="center" valign="top">83.2&#x000B1; 8.1</td>
<td align="center" valign="top">81.8 &#x000B1; 8.1</td>
<td align="center" valign="top">&lt; 0.001</td>
</tr>
<tr>
<td align="left" valign="top">Fasting plasma glucose, mg/dL</td>
<td align="center" valign="top">87.0 &#x000B1; 15.2</td>
<td align="center" valign="top">87.7 &#x000B1; 16.3</td>
<td align="center" valign="top">86.5 &#x000B1; 14.5</td>
<td align="center" valign="top">0.083</td>
</tr>
<tr>
<td align="left" valign="top">Glycated hemoglobin, %</td>
<td align="center" valign="top">5.5 &#x000B1; 0.5</td>
<td align="center" valign="top">5.6 &#x000B1; 0.6</td>
<td align="center" valign="top">5.5 &#x000B1; 0.5</td>
<td align="center" valign="top">&lt; 0.001</td>
</tr>
<tr>
<td align="left" valign="top">Total cholesterol, mg/dL</td>
<td align="center" valign="top">199.2 &#x000B1; 34.1</td>
<td align="center" valign="top">199.6 &#x000B1; 33.9</td>
<td align="center" valign="top">198.9 &#x000B1; 34.3</td>
<td align="center" valign="top">0.644</td>
</tr>
<tr>
<td align="left" valign="top">Triglyceride, mg/dL</td>
<td align="center" valign="top">93.7 &#x000B1; 66.2</td>
<td align="center" valign="top">94.6 &#x000B1; 59.0</td>
<td align="center" valign="top">93.1 &#x000B1; 70.3</td>
<td align="center" valign="top">0.619</td>
</tr>
<tr>
<td align="left" valign="top">HDL-C, mg/dL</td>
<td align="center" valign="top">55.2 &#x000B1; 13.1</td>
<td align="center" valign="top">54.8 &#x000B1; 12.6</td>
<td align="center" valign="top">55.5 &#x000B1; 13.4</td>
<td align="center" valign="top">0.253</td>
</tr>
<tr>
<td align="left" valign="top">LDL-C, mg/dL</td>
<td align="center" valign="top">120.0 &#x000B1; 31.1</td>
<td align="center" valign="top">120.3 &#x000B1; 31.1</td>
<td align="center" valign="top">119.8 &#x000B1; 31.1</td>
<td align="center" valign="top">0.757</td>
</tr>
<tr>
<td align="left" valign="top">TSH, mIU/L</td>
<td align="center" valign="top">2.1 &#x000B1; 1.1</td>
<td align="center" valign="top">2.0 &#x000B1; 1.0</td>
<td align="center" valign="top">2.2 &#x000B1; 1.1</td>
<td align="center" valign="top">&lt; 0.001</td>
</tr>
<tr>
<td align="left" valign="top">Free thyroxine, ng/dL</td>
<td align="center" valign="top">1.3 &#x000B1; 0.2</td>
<td align="center" valign="top">1.3 &#x000B1; 0.2</td>
<td align="center" valign="top">1.3 &#x000B1; 0.2</td>
<td align="center" valign="top">0.883</td>
</tr>
<tr>
<td align="left" valign="top">Metabolic syndrome</td>
<td align="center" valign="top">253 (12.7)</td>
<td align="center" valign="top">115 (15.1)</td>
<td align="center" valign="top">138 (11.3)</td>
<td align="center" valign="top">0.015</td>
</tr>
</tbody></table>
<table-wrap-foot>
<fn><p>Values are presented as number (%) or mean &#x000B1; SD.</p>
<p>HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; TSH, thyroid stimulating hormone.</p></fn>
<fn id="tfn1-kjim-31-1-98"><label>a</label><p>With thyroid nodule vs. without thyroid nodule.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="t2-kjim-31-1-98" position="float">
<label>Table 2.</label>
<caption><p>Metabolic variables and presence of thyroid nodules in subjects with and without metabolic syndrome</p></caption>
<table rules="groups" frame="hsides">
<thead><tr>
<th align="left" valign="middle">Variable</th>
<th align="center" valign="middle">Total (n = 1,990)</th>
<th align="center" valign="middle">With metabolic syndrome (n = 253)</th>
<th align="center" valign="middle">Without metabolic syndrome (n = 1,737)</th>
<th align="center" valign="middle"><italic>p</italic> value<sup><xref rid="tfn2-kjim-31-1-98" ref-type="table-fn">a</xref></sup></th>
</tr></thead>
<tbody>
<tr>
<td align="left" valign="top">Male sex</td>
<td align="center" valign="top">691 (34.7)</td>
<td align="center" valign="top">109 (43.1)</td>
<td align="center" valign="top">582 (33.5)</td>
<td align="center" valign="top">0.004</td>
</tr>
<tr>
<td align="left" valign="top">Age, yr</td>
<td align="center" valign="top">49.8 &#x000B1; 10.0</td>
<td align="center" valign="top">54.9 &#x000B1; 9.0</td>
<td align="center" valign="top">49.1 &#x000B1; 9.9</td>
<td align="center" valign="top">0.058</td>
</tr>
<tr>
<td align="left" valign="top">Systolic blood pressure, mmHg</td>
<td align="center" valign="top">118.4 &#x000B1; 14.3</td>
<td align="center" valign="top">129.8 &#x000B1; 15.5</td>
<td align="center" valign="top">116.8 &#x000B1; 13.3</td>
<td align="center" valign="top">&lt; 0.001</td>
</tr>
<tr>
<td align="left" valign="top">Diastolic blood pressure, mmHg</td>
<td align="center" valign="top">69.2 &#x000B1; 10.1</td>
<td align="center" valign="top">76.3 &#x000B1; 10.2</td>
<td align="center" valign="top">68.1 &#x000B1; 9.7</td>
<td align="center" valign="top">&lt; 0.001</td>
</tr>
<tr>
<td align="left" valign="top">Body mass index, kg/m<sup>2</sup></td>
<td align="center" valign="top">22.9 &#x000B1; 3.1</td>
<td align="center" valign="top">25.8 &#x000B1; 2.8</td>
<td align="center" valign="top">22.5 &#x000B1; 2.9</td>
<td align="center" valign="top">&lt; 0.001</td>
</tr>
<tr>
<td align="left" valign="top">Waist circumference, cm</td>
<td align="center" valign="top">82.3 &#x000B1; 8.1</td>
<td align="center" valign="top">90.3 &#x000B1; 6.9</td>
<td align="center" valign="top">81.2 &#x000B1; 7.6</td>
<td align="center" valign="top">&lt; 0.001</td>
</tr>
<tr>
<td align="left" valign="top">Fasting plasma glucose, mg/dL</td>
<td align="center" valign="top">87.0 &#x000B1; 15.2</td>
<td align="center" valign="top">98.9 &#x000B1; 26.2</td>
<td align="center" valign="top">85.2 &#x000B1; 11.8</td>
<td align="center" valign="top">&lt; 0.001</td>
</tr>
<tr>
<td align="left" valign="top">Glycated hemoglobin, %</td>
<td align="center" valign="top">5.5 &#x000B1; 0.5</td>
<td align="center" valign="top">6.0 &#x000B1; 0.9</td>
<td align="center" valign="top">5.5 &#x000B1; 0.4</td>
<td align="center" valign="top">&lt; 0.001</td>
</tr>
<tr>
<td align="left" valign="top">Total cholesterol, mg/dL</td>
<td align="center" valign="top">199.2 &#x000B1; 34.1</td>
<td align="center" valign="top">208.3 &#x000B1; 39.5</td>
<td align="center" valign="top">197.8 &#x000B1; 33.1</td>
<td align="center" valign="top">&lt; 0.001</td>
</tr>
<tr>
<td align="left" valign="top">Triglyceride, mg/dL</td>
<td align="center" valign="top">93.7 &#x000B1; 66.2</td>
<td align="center" valign="top">173.8 &#x000B1; 102.4</td>
<td align="center" valign="top">82.1 &#x000B1; 49.3</td>
<td align="center" valign="top">&lt; 0.001</td>
</tr>
<tr>
<td align="left" valign="top">HDL-C, mg/dL</td>
<td align="center" valign="top">55.2 &#x000B1; 13.1</td>
<td align="center" valign="top">42.8 &#x000B1; 8.8</td>
<td align="center" valign="top">57.0 &#x000B1; 12.6</td>
<td align="center" valign="top">&lt; 0.001</td>
</tr>
<tr>
<td align="left" valign="top">LDL-C, mg/dL</td>
<td align="center" valign="top">120.0 &#x000B1; 31.1</td>
<td align="center" valign="top">128.3 &#x000B1; 36.0</td>
<td align="center" valign="top">118.8 &#x000B1; 30.1</td>
<td align="center" valign="top">&lt; 0.001</td>
</tr>
<tr>
<td align="left" valign="top">TSH, mIU/L</td>
<td align="center" valign="top">2.1 &#x000B1; 1.1</td>
<td align="center" valign="top">2.2 &#x000B1; 1.1</td>
<td align="center" valign="top">2.1 &#x000B1; 1.1</td>
<td align="center" valign="top">0.497</td>
</tr>
<tr>
<td align="left" valign="top">Free thyroxine, ng/dL</td>
<td align="center" valign="top">1.3 &#x000B1; 0.2</td>
<td align="center" valign="top">1.3 &#x000B1; 0.2</td>
<td align="center" valign="top">1.3 &#x000B1; 0.2</td>
<td align="center" valign="top">0.592</td>
</tr>
<tr>
<td align="left" valign="top">Thyroid nodule</td>
<td align="center" valign="top">764 (38.4)</td>
<td align="center" valign="top">115 (45.5)</td>
<td align="center" valign="top">649 (37.4)</td>
<td align="center" valign="top">0.015</td>
</tr>
<tr>
<td align="left" valign="top">Thyroid nodule size &#x02265; 1 cm</td>
<td align="center" valign="top">186/764 (24.3)</td>
<td align="center" valign="top">38/115 (33.0)</td>
<td align="center" valign="top">148/649 (22.8)</td>
<td align="center" valign="top">0.002</td>
</tr>
<tr>
<td align="left" valign="top">Thyroid nodule multiplicity</td>
<td align="center" valign="top">297/764 (38.9)</td>
<td align="center" valign="top">49/115 (42.6)</td>
<td align="center" valign="top">248/649 (38.2)</td>
<td align="center" valign="top">0.346</td>
</tr>
</tbody></table>
<table-wrap-foot>
<fn><p>Values are presented as number (%) or mean &#x000B1; SD.</p>
<p>HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; TSH, thyroid stimulating hormone.</p></fn>
<fn id="tfn2-kjim-31-1-98"><label>a</label><p>With metabolic syndrome vs. without metabolic syndrome.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="t3-kjim-31-1-98" position="float">
<label>Table 3.</label>
<caption><p>Multivariate binary logistic regression analysis of independent predictors for the presence of thyroid nodules (n = 1,635)</p></caption>
<table rules="groups" frame="hsides">
<thead><tr>
<th align="left" valign="middle">Variable</th>
<th align="center" valign="middle">Odds ratio</th>
<th align="center" valign="middle"><italic>p</italic> value</th>
</tr></thead>
<tbody>
<tr>
<td align="left" valign="top">Female sex (n = 1,140)</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;Age, yr</td>
<td align="center" valign="top">1.059</td>
<td align="center" valign="top">&lt; 0.001</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;Systolic blood pressure, mmHg</td>
<td align="center" valign="top">0.989</td>
<td align="center" valign="top">0.151</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;Diastolic blood pressure, mmHg</td>
<td align="center" valign="top">1.005</td>
<td align="center" valign="top">0.635</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;Waist circumference, cm</td>
<td align="center" valign="top">1.011</td>
<td align="center" valign="top">0.283</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;Glycated hemoglobin, %</td>
<td align="center" valign="top">1.512</td>
<td align="center" valign="top">0.011</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;Triglyceride, mg/dL</td>
<td align="center" valign="top">0.999</td>
<td align="center" valign="top">0.245</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;HDL-C, mg/dL</td>
<td align="center" valign="top">0.995</td>
<td align="center" valign="top">0.360</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;TSH, mIU/L</td>
<td align="center" valign="top">0.828</td>
<td align="center" valign="top">0.001</td>
</tr>
<tr>
<td align="left" valign="top">Male sex (n = 595)</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;Age, yr</td>
<td align="center" valign="top">1.042</td>
<td align="center" valign="top">&lt; 0.001</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;Systolic blood pressure, mmHg</td>
<td align="center" valign="top">0.989</td>
<td align="center" valign="top">0.352</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;Diastolic blood pressure, mmHg</td>
<td align="center" valign="top">1.005</td>
<td align="center" valign="top">0.741</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;Waist circumference, cm</td>
<td align="center" valign="top">1.042</td>
<td align="center" valign="top">0.005</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;Glycated hemoglobin, %</td>
<td align="center" valign="top">0.951</td>
<td align="center" valign="top">0.734</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;Triglyceride, mg/dL</td>
<td align="center" valign="top">1.000</td>
<td align="center" valign="top">0.780</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;HDL-C, mg/dL</td>
<td align="center" valign="top">0.999</td>
<td align="center" valign="top">0.882</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;TSH, mIU/L</td>
<td align="center" valign="top">0.714</td>
<td align="center" valign="top">&lt; 0.001</td>
</tr>
</tbody></table>
<table-wrap-foot>
<fn><p>HDL-C, high density lipoprotein cholesterol; TSH, thyroid stimulating hormone.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
</back></article>